Finance

Lists
Why is CNTX up 6.82%?
Dive Deeper
CNTX:NASDAQ
Context Therapeutics Inc
$0.20
+6.82%
(+0.013) 1D
$0.20
-2.43% (-0.0049)
After hours
Closed: Nov 2, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CNTX...
Open
$0.19
High
$0.21
Low
$0.19
Mkt. cap
18.47M
Avg. vol.
1.07M
Volume
0.00
52-wk high
$3.62
52-wk low
$0.19
EPS
-$0.48
Beta
1.71
Shares outstanding
91.88M
No. of employees
15
Open
$0.19
High
$0.21
Low
$0.19
Mkt. cap
18.47M
Avg. vol.
1.07M
Volume
0.00
52-wk high
$3.62
52-wk low
$0.19
EPS
-$0.48
Beta
1.71
Shares outstanding
91.88M
No. of employees
15
News stories
From web sources and news partners
About Context Therapeutics Inc
CEO-
Employees15
Founded2015
HeadquartersPhiladelphia, Pennsylvania, United States
SectorPharmaceutical industry
Websitecontexttherapeutics.com
Analyst ratings
Based on 7 analysts giving stock ratings to CNTX in the past 3 months
Strong buy
Buy
6
Hold
1
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for CNTX in the last 3 months.
Highest
Current $0.20
$5.00 (+2,375.25%)
Average
$3.50 (+1,632.67%)
Lowest
$2.00 (+890.10%)
Analyst
Recommendation
Action
Price target
Projected
Date
Biren Amin
Piper Sandler
Buy
Maintained
$5.00
+2,375.2%
10/26/2026
Jason McCarthy
Maxim Group
Buy
Maintained
$4.00
+1,880.2%
08/10/2026
Charles Zhu
LifeSci Capital
Hold
Downgraded
$2.00
+890.1%
08/08/2026
Silvan Turkcan
Citizens JMP
Buy
Maintained
$3.00
+1,385.1%
08/06/2026
Matt Phipps
William Blair
Buy
Reiterated
-
-
08/06/2026
Boris Peaker
JonesTrading
Buy
Reiterated
$2.00
+890.1%
08/06/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
$5.00
+2,375.2%
08/06/2026
Paul Jeng
Guggenheim
Buy
Maintained
$5.00
+2,375.2%
05/06/2026
Soumit Roy
JonesTrading
Buy
Maintained
$7.00
+3,365.3%
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
8.72M
11.84M
7.02M
12.53M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.89M
1.96M
2.33M
2.44M
Operating expense
10.61M
13.80M
9.34M
14.97M
Total operating expenses
10.61M
13.80M
9.34M
14.97M
Operating income
-10.61M
-13.80M
-9.34M
-14.97M
Other non operating income
83.47K
96.56K
-
-9.60K
EBT including unusual items
-9.69M
-13.03M
-8.68M
-14.56M
EBT excluding unusual items
-9.69M
-13.03M
-8.68M
-14.56M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-9.69M
-13.03M
-8.68M
-14.56M
Net profit margin
-
-
-
-
Earnings per share
-0.10
-0.14
-0.09
-0.15
Interest and investment income
833.77K
682.48K
520.14K
418.66K
Interest expense
-
-
-
-
Net interest expenses
833.77K
682.48K
520.14K
418.66K
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.61M
-13.80M
-9.34M
-14.96M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps